Exiqon

The firm's revenues rose 32 percent in the first half of the year. It has since undertaken a restructuring to save money.

New Releases

Premium

Exiqon's BRAF mutation analysis

BioArray Briefs: 2009.03.24

Premium

Quest Diagnostics, Centre for Proteomic and Genomic Research, SimuGen, Arrayit, Phalanx, Rosetta Biosoftware, Exiqon, Norgen Biotek, TcLand Expression, Genedata, GeneGo, Entelos, Integrated DNA Technologies, VH Bio, SciGene, Inter Medico

Affy transferred ownership of the 10,000-square-foot Clinical Services Lab to Navigenics earlier this year though an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.

The company last month presented data showing that the test could be used to detect cancer, but more work is needed to refine the test so that it can distinguish between different types of malignancies.

People In the News

Lai Named SVP of R&D at Gen-Probe, Jorge Leon Joins ParagonDx SAB, Strategic Diagnostics Hires Two Execs, and More.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.